Safety Study of CC312 in Autoimmune Disease Patients

Abroad (travel likely)RecruitingEARLY_PHASE1

Conditions

Systemic Lupus Erythematosus (SLE) · Idiopathic Inflammatory Myopathy (IIM) · Systemic Sclerosis (SSc) · Rheumatoid Arthritis (RA) · Primary Immune Thrombocytopenia (ITP) · Autoimmune Hemolytic Anemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China, China
Contact: Study coordinator (Junyuan Qi) · qijy@ihcams.ac.cn · 022-23909095
Contact: Principal Investigator (Junyuan Qi)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus Erythematosus (SLE) · Lupus Nephritis (LN) · Systemic Sclerosis (SSc)

Abroad (travel likely)RecruitingPHASE1

Hefei, China

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

Autoimmune Diseases · Systemic Lupus Erythematosus · Systemic Sclerosis

Abroad (travel likely)RecruitingEARLY_PHASE1

Shanghai, China

Safety and Efficacy Study of CC312 for Moderate to Severe SLE

SLE - Systemic Lupus Erythematosus

Abroad (travel likely)RecruitingPHASE1

Chengdu, China

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

Systemic Lupus Erythematosus · Inflammatory Myopathy · Systemic Sclerosis (SSc)

Abroad (travel likely)RecruitingPHASE2

Beijing, China